Bio-Rad Laboratories vs Insulet

Bio-Rad Laboratories (BIO), health care, and Insulet (PODD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Insulet is worth $10.1B on the stock market and Bio-Rad Laboratories $9.6B: Insulet is valued at 5% more. Bio-Rad Laboratories trades at 9.5 times earnings and Insulet at 23.7; operating margins in their latest fiscal years were 1.83% and 17.5%. Over the past year Bio-Rad Laboratories's share price has moved +17.1% and Insulet's -56.4%.

Key facts

Bio-Rad Laboratories market value
$9.6B
Insulet market value
$10.1B
Bio-Rad Laboratories P/E
9.5
Insulet P/E
23.7
Bio-Rad Laboratories revenue
$2.6BFY to 2025-12-31
Insulet revenue
$2.7BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Bio-Rad Laboratories vs Insulet: every measure side by side
Measure Bio-Rad Laboratories Insulet
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$9.6Blower$10.1Bhigher
Revenue$2.6Blower$2.7Bhigher
Earnings$759.9Mhigher$247.1Mlower
Employees7,450higher5,400lower
Total assets$10.6Bhigher$3.2Blower
Valuation
P/E9.5lower23.7higher
P/S3.7higher3.7lower
P/B1.3lower6.4higher
Dividend yield0.00%0.00%
Profitability
Operating margin1.83%lower17.5%higher
Balance sheet
Net assets$7.5Bhigher$1.5Blower
Total liabilities$3.1Bhigher$1.7Blower
Total debt$1.2Bhigher$949.2Mlower
Cash on hand$529.8Mlower$716.1Mhigher
Price change
Today-0.57%lower+0.03%higher
1 year+17.1%higher-56.4%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Bio-Rad Laboratories only (3)

Insulet only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns BIO · Who owns PODD

Further comparisons

Learn

Questions and answers

Which is bigger, Bio-Rad Laboratories or Insulet?

By market value, Insulet is the larger: $10.1B against $9.6B for Bio-Rad Laboratories. By revenue in its latest fiscal year, Insulet is the larger: $2.7B against $2.6B for Bio-Rad Laboratories.

Which has the higher P/E ratio?

Insulet: 23.7, against 9.5 for Bio-Rad Laboratories. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Insulet: 17.5%, against 1.83% for Bio-Rad Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Bio-Rad Laboratories: $1.2B, against $949.2M for Insulet. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bio-Rad Laboratories and Insulet?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Bio-Rad Laboratories and 1 holds Insulet.

Cite this page

Funkfolio, “Bio-Rad Laboratories vs Insulet”, data as of 17 November 2026. https://funkfolio.com/compare/bio-vs-podd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.